FTAdviser.com

Advertising

The team's central view on the US has become more positive. Rather than taking a material overweight, though, Mr Lanning plans to switch core exposure in Gartmore's more aggressive funds of funds from Martin Currie's £321m North American fund to its recently launched High Alpha counterpart, marking a shift away from beta reliance. Both Martin Currie funds are run by Tom Walker and David Forsyth.

"We are looking at the funds we hold and looking to make them sweat a bit more," Mr Lanning explained. "For our more active funds that will involve moving to the alpha product."

A similar transition is anticipated for Gartmore's European exposure, with Chris Rice's £384.7m Cazenove European vehicle expected to be supplemented with a more alpha-generative product, although Mr Lanning said he was still exploring this option. At the moment the multi-manager range's European content is roughly benchmark-neutral.

"Rather than increasing exposure to Europe we will use a high alpha vehicle to get that exposure," Mr Lanning said.

He added the team was hoping to broaden its use of the Nurs structure across the board, examining alternatives such as funds of hedge funds and target return funds.

In terms of Gartmore's overall multi-manager suite, the three smaller products - the £6.1m Active, £4.1m Global Alpha and £2.3m UK Alpha funds - are likely to be merged into one alpha-focused fund, although Mr Lanning said plans were still being finalised.